Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 1, 2005 - Issue 2
Submit an article Journal homepage
208
Views
74
CrossRef citations to date
0
Altmetric
Review

Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1

Peter H Roos Institut für Arbeitsphysiologie an der Universität Dortmund (IfADo), Leibniz Research Centre for Working Environment and Human Factors, Ardeystr. 67, D-44139 Dortmund, Germany. [email protected]
&
Hermann M Bolt Institut für Arbeitsphysiologie an der Universität Dortmund (IfADo), Leibniz Research Centre for Working Environment and Human Factors, Ardeystr. 67, D-44139 Dortmund, Germany. [email protected]
Pages 187-202 | Published online: 16 Aug 2005

Bibliography

  • RODIN SN, RODIN AS: Origins and selection of p53 mutations in lung carcinogenesis. Semin. Cancer Biol. (2005) 15:103–112.
  • HUYNH H: Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/ p130) in hepatocellular carcinoma. Carcinogenesis (2004) 25:1485–1494.
  • KIM WY, KAELIN WG: Role of VHL gene mutation in human cancer. J. Clin. Oncol. (2004) 22:4991–5004.
  • MILLER F, KENTSIS A, OSMAN R, PAN ZQ: Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL: HIF-1alpha complex. J. Biol. Chem. (2005) 280:7986–7996.
  • THIER R, GOLKA K, BRÜNING T, KO Y, BOLT HM: Genetic susceptibility to environmental toxicants: the interface between human and experimental studies in the development of new toxicological concepts. Toxicol. Lett. (2002) 127(1–3):321–327.
  • CHARLOUX A, QUOIX E, WOLKOVE N, SMALL D, PAULI G, KREISMAN H: The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int. J. Epidemiol. (1997) 26:14–23.
  • JANSSEN-HEIJNEN ML, COEBERGH JW: The changing epidemiology of lung cancer in Europe. Lung Cancer (2003) 41:245–258.
  • DE LAS HERAS M, GONZALEZ L, SHARP JM: Pathology of ovine pulmonary adenocarcinoma. Curr. Top. Microbiol. Immunol. (2003) 275:25–54.
  • OGHISO Y, YAMADA Y: Immunohistochemical study on cellular origins of at lung tumors induced by inhalation exposures to plutonium dioxide aerosols as compared to those by X-ray irradiation. J. Radiat. Res. (2002) 43:301–311.
  • NISHIMURA M, YAGUTI H, YOSHITSUGU H, NAITO S, SATOH T: Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi (2003) 123:369–375.
  • DING X, KAMINSKY LS: Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. (2003) 43:149–173.
  • PETERSON LA, HECHT SS: O6- methylguanine is a critical determinant of 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone tumorigenesis in A/J mouse lung. Cancer Res. (1991) 51:5557–5564.
  • WANG H, TAN W, HAO B et al.: Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res. (2003) 63:8057–8061.
  • BELINSKY SA, WHITE CM, DEVEREUX TR, SWENBERG JA, ANDERSON MW: Cell selective alkylation of DNA in rat lung following low dose exposure to the tobacco specific carcinogen 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res. (1987) 47:1143–1148.
  • RIOUX N, CASTONGUAY A: Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. (1998) 58:5354–5360.
  • HARRIS RE, BEEBE-DONK J, SCHULLER HM: Chemoprevention of lung cancer by non-steroidal antiinflammatory drugs among cigarette smokers. Oncol. Rep. (2002) 9:693–695.
  • CAMPA D, ZIENOLDDINY S, MAGGINI V, SKAUG V, HAUGEN A, CANZIAN F: Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis (2004) 25:229–235.
  • DEVANESAN PD, CREMONESI P, NUNNALLY JE, ROGAN EG, CAVALIERI EL: Metabolism and mutagenicity of dibenzo[a,e]pyrene and the very potent environmental carcinogen dibenzo[a,l]pyrene. Chem. Res. Toxicol. (1990) 3:580–586.
  • PIIPARI R, SAVELA K, NURMINEN T et al.: Expression of CYP1A1, CYP1B1 and CYP3A, and polycyclic aromatic hydrocarbon-DNA adduct formation in bronchoalveolar macrophages of smokers and non-smokers. Int. J. Cancer (2000) 86:610–616.
  • ROSS JA, NELSON GB, WILSON KH et al.: Adenomas induced by polycyclic aromatic hydrocarbons in strain A/J mouse lung correlate with time-integrated DNA adduct levels. Cancer Res. (1995) 55:1039–1044.
  • DENISSENKO MF, PAO A, TANG M, PFEIFER GP: Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science (1996) 274:430–432.
  • WESTRA WH, OFFERHAUS GJ, GOODMAN SN et al.: Overexpression of the p53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am. J. Surg. Pathol. (1993) 17:213–220.
  • WARREN AJ, SHIELDS PG: Molecular epidemiology: carcinogen-DNA adducts and genetic susceptibility. Proc. Soc. Exp. Biol. Med. (1997) 216:172–180.
  • HOULSTON RS: CYP1A1 polymorphisms and lung cancer risk: a meta-analysis. Pharmacogenetics (2000) 10:105–114.
  • DRESLER CM, FRATELLI C, BABB J, EVERLEY L, EVANS AA, CLAPPER ML: Gender differences in genetic susceptibility for lung cancer. Lung Cancer (2000) 30:153–160.
  • SATO M, SATO T, IZUMO T, AMAGASA T: Genetically high susceptibility to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes. Oral Oncol. (2000) 36:267–271.
  • NAIR U, BARTSCH H: Metabolic polymorphisms as susceptibility markers for lung and oral cavity cancer. IARC Sci. Publ. (2001) 154:271–290.
  • QUINONES L, LUCAS D, GODOY J et al.: CYP1A1, CYP2E1 and GSTM1 genetic polymorphisms. The effect of single and combined genotypes on lung cancer susceptibility in Chilean people. Cancer Lett. (2001) 174:35–44.
  • BARTSCH H, NAIR U, RISCH A, ROJAS M, WIKMAN H, ALEXANDROV K: Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomarkers Prev. (2000) 9:3–28.
  • HOULSTON RS: Glutathione Stransferase M1 status and lung cancer risk: a meta-analysis. Cancer Epidemiol. Biomarkers Prev. (1999) 8:675–682.
  • WATANABE J, SHIMADA T, GILLAM EM et al.: Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics (2000) 10:25–33.
  • SPIVACK SD, HURTEAU GJ, FASCO MJ, KAMINSKY LS: Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors. Clin. Cancer Res. (2003) 9:6002–6011.
  • SHIMADA T, MARTIN MV, PRUESS-SCHWARTZ D, MARNETT LJ, GUENGERICH FP: Roles of individual human cytochrome P450 enzymes in the bioactivation of benzo(a)pyrene, 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, and other dihydrodiol derivatives of polycyclic aromatic hydrocarbons. Cancer Res. (1989) 49:6304–6312.
  • DALLY H, EDLER L, JAGER B et al.: The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics (2003) 13:607–618.
  • YEH KT, CHEN JC, CHEN CM, WANG YF, LEE TP, CHANG JG: CYP3A5*1 is an inhibitory factor for lung cancer in Taiwanese. Kaohsiung J. Med. Sci. (2003) 19:201–207.
  • NISHIMURA M, NAITO S, YOKOI T: Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab. Pharmacokinet. (2004) 19:135–149.
  • SOBTI RC, SHARMA S, JOSHI A, JINDAL SK, JANMEJA A: CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population. Biomarkers (2003) 8:415–428.
  • LAFOREST L, WIKMAN H, BENHAMOU S et al.: CYP2D6 gene polymorphism in Caucasian smokers: lung cancer susceptibility and phenotypegenotype relationships. Eur. J. Cancer (2000) 36:1825–1832.
  • ROSTAMI-HODJEGAN A, LENNARD MS, WOODS HF, TUCKER GT: Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics (1998) 8:227–238.
  • CRESPI CL, PENMAN BW, GELBOIN HV, GONZALEZ FJ: A tobacco smoke-derived nitrosamine, 4- (methylnitrosamino)-1-(3-pyridyl)-1- butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis (1991) 12:1197–201.
  • PENMAN BW, REECE J, SMITH T et al.: Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. Pharmacogenetics (1993) 3:28–39.
  • FUJITA K, KAMATAKI T: Predicting the mutagenicity of tobacco-related Nnitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ. Mol. Mutagen. (2001) 38:339–346.
  • ABDEL-RAHMAN SZ, SALAMA SA, AU WW, HAMADA FA: Role of polymorphic CYP2E1 and CYP2D6 genes in NNK-induced chromosome aberrations in cultured human lymphocytes. Pharmacogenetics (2000) 10:239–249.
  • AGÚNDEZ JAG, GALLARDO L, LEDESMA MC et al.: Functionally active duplications of the CYP2D6 gene are more prevalent among larynx and lung cancer patients. Oncology (2001) 61:59–63.
  • AGÚNDEZ JAG: Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab. (2004) 5:211–224.
  • TSUNEOKA Y, FUKUSHIMA K, MATSUO Y, ICHIKAWA Y, WATANABE Y: Genotype analysis of the CYP2C19 gene in the Japanese population. Life Sci. (1996) 59:1711–1715.
  • BENHAMOU S, BOUCHARDY C, DAYER P: Lung cancer risk in relation to mephenytoin hydroxylation activity. Pharmacogenetics (1997) 7:157–159.
  • SHI WX, CHEN SQ: Frequencies of poor metabolizers of cytochrome P450 2C19 in esophagus cancer, stomach cancer, lung cancer and bladder cancer in Chinese population. World J. Gastroenterol. (2004) 10:1961–1963.
  • KLOSE TS, BLAISDELL JA, GOLDSTEIN JA: Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs. J. Biochem. Mol. Toxicol. (1999) 13:289–295.
  • KAMATAKI T, FUJITA K, NAKAYAMA K, YAMAZAKI Y, MIYAMOTO M, ARIYOSHI N: Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP. Drug Metab. Rev. (2002) 34:667–676.
  • RAUNIO H, HAKKOLA J, HUKKANEN J et al.: Expression of xenobiotic-metabolizing CYPs in human pulmonary tissue. Exp. Toxicol. Pathol. (1999) 51:412–417.
  • ANDERSON E: Cellular homeostasis and the breast. Maturitas (2004) 48(Suppl. 1): S13–S17.
  • CHEN S: Aromatase and breast cancer. Front. Biosci. (1998) 3:d922–d933.
  • BOLT HM, GÖBEL P: Formation of estrogens from androgens by human subcutaneous adipose tissue in vitro. Horm. Metab. Res. (1972) 4:312–313.
  • HOLMBERG L, ANDERSON H; HABITS STEERING AND DATA MONITORING COMMITTEES: HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomised comparison: trial stopped. Lancet (2004) 363(9407):453–455.
  • BOLT HM: Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer’s pioneering ideas to modern concepts. Drug Metab. Rev. (2004) 36(3–4):497–509.
  • JUSTENHOVEN C, HAMANN U, PESCH B et al.: ERCC2 Genotypes and a corresponding haplotype are linked with breast cancer risk in a German population. Cancer Epidemiol. Biomarkers Prev. (2004) 13(12):2059–2064.
  • RYLANDER-RUDQVIST T, WEDREN S, GRANATH F et al.: Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk. Carcinogenesis. (2003) 24(9):1533–1539.
  • MITRUNEN K, KATAJA V, ESKELINEN M et al.: Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk. Pharmacogenetics. (2002) 12(1):67–72.
  • PARK SK, YIM DS, YOON KS et al.: Combined effect of GSTM1, GSTT1, and COMT genotypes in individual breast cancer risk. Breast Cancer Res. Treat. (2004) 88:55–62.
  • TSUCHIYA Y, NAKAJIMA M, KYO S, KANAYA T, INOUE M, YOKOI T: Human CYP1B1 is regulated by estradiol via oestrogen receptor. Cancer Res. (2004) 64(9):3119–3125.
  • HANNA IH, DAWLING S, ROODI N, GUENGERICH FP, PARL FF: Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in oestrogen hydroxylation activity. Cancer Res. (2000) 60(13):3440–3444.
  • IVERSON SL, SHEN L, ANLAR N, BOLTON JL: Bioactivation of estrone and its catechol metabolites to quinoidglutathione conjugates in rat liver microsomes. Chem. Res. Toxicol. (1996) 9(2):492–499.
  • BOLT HM, KAPPUS H: Irreversible binding of ethynyl-estradiol to protein and nucleic acids as catalyzed by rat liver microsomes and mushroom tyrosinase. J. Steroid Biochem. (1974) 5:179–184.
  • HACHEY DL, DAWLING S, ROODI N, PARL FF: Sequential action of Phase I and II enzymes cytochrome P450 1B1 and glutathione S-transferase P1 in mammary oestrogen metabolism. Cancer Res. (2003) 63(23):8492–8499.
  • DAWLING S, HACHEY DL, ROODI N, PARL FF: In vitro model of mammary oestrogen metabolism: structural and kinetic differences between catechol oestrogens 2- and 4-hydroxyestradiol. Chem. Res. Toxicol. (2004) 17(9):1258–1264.
  • DAWLING S, ROODI N, PARL FF: Methoxyoestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1. Cancer Res. (2003) 63(12):3127–3132.
  • PARKIN DM: International variation. Oncogene (2004) 23:6329–6340.
  • BRAUERS A, MANEGOLD E, BUETTNER R, BARON JM, MERK HF, JAKSE G: Cytochrome P450 isoenzyme mRNA expression pattern in human urinary bladder malignancies and normal urothelium. Cancer Detect. Prev. (2000) 24:356–363.
  • IMAOKA S, YONEDA Y, MATSUDA T, DEGAWA M, FUKUSHIMA S, FUNAE Y: Mutagenic activation of urinary bladder carcinogens by CYP4B1 and the presence of CYP4B1 in bladder mucosa. Biochem. Pharmacol. (1997) 54:677–683.
  • DEGEN GH, SCHLATTJAN JH, MAHLER S, FOLLMANN W, GOLKA K: Comparative metabolic activation of benzidine and N-acetylbenzidine by prostaglandin H synthase. Toxicol. Lett. (2004) 151:135–142.
  • WOLF A, KUTZ A, PLÖTTNER S et al.: The effect of benzo(a)pyrene on porcine urinary bladder epithelial cells analyzed for the expression of selected genes and cellular toxicological endpoints. Toxicology (2005) 207:255–269.
  • IMAOKA S, YONEDA Y, SUGIMOTO T et al.: CYP4B1 is a possible risk factor for bladder cancer in humans. Biochem. Biophys. Res. Commun. (2000) 277:776–780.
  • VAZIRI SA, HUGHES NC, SAMPSON H, DARLINGTON G, JEWETT MA, GRANT DM: Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects. Pharmacogenetics (2001) 11:7–20.
  • GAGO-DOMINGUEZ M, BELL DA, WATSON MA et al. : Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and Nacetyltransferases 1 and 2. Carcinogenesis (2003) 24:483–489.
  • LEE SW, JANG IJ, SHIN SG et al.: CYP1A2 activity as a risk factor for bladder cancer. J. Korean Med. Sci. (1994) 9:482–489.
  • IMAOKA S, YONEDA Y, SUGIMOTO T et al.: Androgen regulation of CYP4B1 responsible for mutagenic activation of bladder carcinogens in the rat bladder: detection of CYP4B1 mRNA by competitive reverse transcriptionpolymerase chain reaction. Cancer Lett. (2001) 166:119–123.
  • RYLANDER T, NEVE EP, INGELMAN-SUNDBERG M, OSCARSON M: Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1). Biochem. Biophys. Res. Commun. (2001) 281:529–535.
  • BROCKMÖLLER J, CASCORBI I, KERB R, ROOTS I: Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. (1996) 56:3915–3925.
  • ANWAR WA, ABDEL-RAHMAN SZ, EL-ZEIN RA, MOSTAFA HM, AU WW: Genetic polymorphism of GSTM1, CYP2E1 and CYP2D6 in Egyptian bladder cancer patients. Carcinogenesis (1996) 17:1923–1929.
  • CHINEGWUNDOH FI, KAISARY AV: Polymorphism and smoking in bladder carcinogenesis. Br. J. Urol. (1996) 77:672–675.
  • KOMHOFF M, GUAN Y, SHAPPELL HW et al. : Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am. J. Pathol. (2000) 157:29–35.
  • GRUBBS CJ, LUBET RA, KOKI AT et al.: Celecoxib inhibits N-butyl-N-(4- hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. (2000) 60:5599–5602.
  • KANG S, KIM YB, KIM person-group-type="author">MH et al. : Polymorphism in the nuclear factor kappa- B binding promoter region of cyclooxygenase-2 is associated with an increased risk of bladder cancer. Cancer Lett. (2005) 217:11–16.
  • BROCKMÖLLER J, KAISER R, KERB R, CASCORBI I, JAEGER V, ROOTS I: Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. Pharmacogenetics (1996) 6:535–545.
  • BRENNAN P, BOFFETTA P: Mechanistic considerations from the molecular epidemiology of head and neck cancer. In: Mechanisms of Carcinogenesis. IARC Scientific Publications (2004) 157:393–414.
  • NIMURA Y, YOKOYAMA S, FUJIMORI M et al.: Genotyping of the CYP1A1 and GSTM1 genes in esophageal carcinoma patients with special reference to smoking. Cancer (1997) 80:852–857.
  • OLSHAN AF, WEISSLER MC, WATSON MA, BELL DA: GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol. Biomarkers Prev. (2000) 9:185–191.
  • MCWILLIAMS JE, EVANS AJ, BEER TM et al.: Genetic polymorphisms in head and neck cancer risk. Head Neck (2000) 22:609–617.
  • SREELEKHA TT, RAMADAS K, PANDEY M, THOMAS G, NALINAKUMARI KR, PILLAI MR: Genetic polymorphism of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol. (2001) 37:593–598.
  • MORITA S, YANO M, TSUJINAKA T et al.: Genetic polymorphisms of drugmetabolizing enzymes and susceptibility to head-and-neck squameous-cell carcinoma. Int. J. Cancer (1999) 80:685–688.
  • GRONAU S, KOENIG-GREGER D, JERG M, REICHELMANN H: Gene polymorphisms in detoxification enzymes as susceptibility factor for head and neck cancer? Otolaryngol. Head Neck Surg. (2003) 128:674–680.
  • GEISLER SA, OLSHAN AF: GSTM1, GSTT1, and the risk of squamous cell carcinoma of the head and neck: a minireview. Am. J. Epidemiol (2001) 154:95–105.
  • TAN W, SONG N, WANG GQ et al.: Impact of genetic polymorphisms in cytochrome P450 2E1 and glutathione S-transferases M1, T1, and P1 on susceptibility to esophageal cancer among high-risk individuals in China. Cancer Epidemiol. Biomarkers Prev. (2000) 9:551–556.
  • TAN W, CHEN GF, XING DY, SONG CY, KADLUBAR FF, LIN DX: Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int. J. Cancer (2001) 95:96–101.
  • CAMUS A-M, GENESTE O, HONKAKOSKI P et al.:, High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol. Carcinogen. (1993) 7:268–275.
  • CHEN SC, ZHOU L, DING X, MIRVISH SS: Depentylation of the rat esophageal carcinogen, methyl-Npentylnitrosamine, by microsomes from various human and rat tissues and by cytochrome P450 2A3. Drug Metab. Dispos. (2001) 29:1221–1228.
  • NEUHAUS T, KO YD, LORENZEN K et al.: Association of cytochrome P450 2E1 polymorphisms and head and neck squameous cell cancer. Toxicol. Lett. (2004) 151:273–282.
  • KO Y, ABEL J, HARTH V et al.: Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res. (2001) 61:4398–4404.
  • WEBER A, TANNAPFEL A, WITTEKIND C, BOOTZ F: Carcinogeninduced site-specific mutagenesis and genetic susceptibility in squamous cell carcinoma of the head and neck. Onkologie (2002) 25:8–13.
  • BANASZEWSKI J, SZEMEJA Z, SZYFTER W, SZYFTER K, BARANCZEWSKI P, MOLLER L: Analysis of aromatic DNA adducts in laryngeal biopsies. Eur. Arch. Otorhinolaryngol. (2000) 257:149–153.
  • DEGAWA M, STERN SJ, MARTIN MV et al.: Metabolic activation and carcinogen- DNA adduct detection in human larynx. Cancer Res. (1994) 15:4915–4919.
  • BADAWI AF, STERN SJ, LANG NP, KADLUBAR FF: Cytochrome P450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer suceptibility. Prog. Clin. Biol. Res. (1996) 395:109–140.
  • SUTTER TR, TANG YM, HAYES CL et al.: Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem. (1994) 269:13092–13099.
  • MURRAY GI, TAYLOR MC, MCFADYEN MC et al.: Tumor-specific expression of cytochrome P 450 CYP1B1. Cancer Res. (1997) 57:3026–3031.
  • MURRAY GI, MELVIN WT, GREENLEE WF, BURKE MD: Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. Toxicol. (2001) 41:297–316.. Standard review on CYP1B1.
  • BAILEY LR, ROODI N, DUPONT WD, PARL FF: Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. (1998) 58:5038–5041[Erratum (1999) Cancer Res. 59:1388].
  • MCLELLAN RA, OSCARSON M, HIDESTRAND M et al.: Characterization and functional analysis of two common human cytochrome P450 1B1 variants. Arch. Biochem. Biophys. (2000) 378:175–181.
  • LI DN, SEIDEL A, PRITCHARD MP, WOLF CR, FRIEDBERG T: Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics (2000) 10:343–353.
  • BRUNING T, ABEL J, KOCH B et al.: Real-time PCR-analysis of the cytochrome P450 1B1 codon 432-polymorphism. Arch. Toxicol. (1999) 73:427–430.
  • SHIMADA T, HAYES CL, SPINK DC et al.: Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res. (1996) 56:2979–2984.
  • CRESPI CL, PENMAN BW, STEINER DT, SMITH T, YANG CS, SUTTER TR: Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens. Carcinogenesis (1997) 12:83–89.
  • SPINK DC, HAYES CL, YOUNG NR et al.: The effects of 2,3,7,8- tetrachlorodibeno-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 betaestradiol 4-hydroxylase. J. Steroid Biochem. Molec. Biol. (1994) 51:251–258.
  • HAYES CL, SPINK DC, SPINK BC, CAO JQ, WALKER NJ, SUTTER TR: 17β-Estradiol hydroxylation catalyzed by human cytochrome mP450 1B1. Proc. Natl. Acad. Sci. USA (1996) 93:9776–9781.
  • KIM JH, STANSBURY KH, WALKER NJ, TRUSH MA, STRICKLAND PT, SUTTER TR: Metabolism of benzo(a)pyrene and benzo(a)pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis (1998) 19:1847–1853[Erratum, 1999: Carcinogenesis 20:515].
  • HEIDEL SM, MACWILLIAMS PS, BAIRD WM et al.: Cytochrome P4501B1 mediates induction of bone marrow cytotoxicity and preleukemia cells in mice treated with 7,12- dimethylbenz(a)anthracene. Cancer Res. (2000) 60:3454–3460.
  • LUCH A, COFFING SL, TANG YM et al.: Stable expression of human cytochrome P450 1B1 in V79 Chinese hamster cells and metabolically catalyzed DNA adduct formation of dibenzo[a,l]pyrene. Chem. Res. Toxicol. (1998) 11:686–695.
  • LUCH A, SCHOBER W, SOBALLA VJ et al.: Metabolic activation of dibenzo[a,l]pyrene by human cytochrome P450 1A1 and P450 1B1 expressed in V79 Chinese hamster cells. Chem. Res. Toxicol. (1999) 12:353–364.
  • SHIMADA T, WATANABE J, KAWAJIRI K et al.: Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis (1999) 20:1607–1613.
  • SHIMADA T, WATANABE J, INOUE K, GUENGERICH FP, GILLAM EM: Specificity of 17beta-oestradiol and benzo[a]pyrene oxidation by polymorphic human cytochrome P4501B1 variants substituted at residues 48, 119 and 432. Xenobiotica (2001) 31:163–176.
  • KISS I, SANDOR J, PAJKOS G, BOGNER B, HEGEDUS G, EMBER I: Colorectal cancer risk in relation to genetic polymorphism of cytochrome P450 1A1, 2E1, and glutathione-S-transferase M1 enzymes. Anticancer Res. (2000) 20:519–522.
  • YIN PH, LEE HC, CHAU GY et al.: Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females. Cancer Lett. (2004) 212:195–201.
  • HAN XM, OU-YANG DS, LU PX et al.: Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics (2001) 11:429–435.
  • WOJNOWSKI L, TURNER PC, PEDERSEN B et al.: Increased levels of aflatoxin-albumin adducts are associated with CYP3A5 polymorphisms in The Gambia, West Africa. Pharmacogenetics (2004) 14:691–700.
  • LONGUEMAUX S, DELOMENIE C, GALLOU C et al.: Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes. Cancer Res. (1999) 59:2903–2908.
  • SASAKI M, TANAKA Y, OKINO ST et al.: Polymorphisms of the CYP1B1 gene as risk factors for human renal cell cancer. Clin. Cancer Res. (2004) 10:2015–2019.
  • FARKER K, LEHMANN MH, OELSCHLAGEL B et al.: Impact of CYP2E1 genotype in renal cell and urothelial cancer patients. Exp. Toxicol. Pathol. (1998) 50:425–431.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.